China researchers have confirmed widespread rumors circulating in the scientific community that they had performed landmark work using a gene-editing technique on human embryos--usually an ethical no-no. Regardless of the debate surrounding the work, they concluded that what they were attempting was not feasible.
China officials have proposed changes in the country's patent laws intended to take its intellectual-property protections beyond the U.N. standards and to a higher level. The State Intellectual Property Office said the emphasis now is on patent commercialization as well as protection.
Vietnam has become the 39th nation cleared for global exports of the vaccines it makes, joining an increasingly crowded field of local champions to multinational heavyweights. The World Health Organization gave that clearance recently for a country that expects to be a leading producer within the next 20 to 30 years.
Shanghai-based WuXi PharmaTech said its subsidiary WuXi NextCODE Genomics has joined with U.S.-based DNAnexus to offer a wider range of genomics services worldwide, including cloud-based services, according to a press release on Wednesday.
A leading Chinese health official renewed a call for greater access to medicines and other treatments through a more competitive distribution system and reforms in the way hospitals operate.
The FDA may be having difficulty getting inspectors stationed in China, but that has not stopped it from issuing warning letters to drug and ingredient makers there who have issues. The agency posted a second warning letter today for API maker Yunnan Hande Bio-Tech, which was previously cited in 2010.
China authorities at the highest level are acting on legislation that would, among other things, decentralize drug industry regulation and free some price controls.
The buzz around biotech in Asia has centered on friends and family bootstrap operations in China, local investor support in Taiwan and onto more formal state-backed incubation efforts in Japan, South Korea and Singapore along with boutique venture capital firms and investment arms of multinationals such as Eli Lilly Ventures.
The head of the Novartis unit in China, Novartis Greater China, believes the company's research-and-development operations are ahead of most competition, giving it a leg up in meeting the demands of aging populations in China and emerging markets.
This may be why your mother told you never to air your dirty laundry in public: there's an uproar in Beijing over the bodies of six dead cats hanging on a clothesline outside Macro-Union Pharmaceutical.